Regencell Bioscience Limited is a Hong Kong compan
Post# of 6704
(Total Views: 267)
Posted On: 10/19/2022 7:34:07 AM
Regencell Bioscience Limited is a Hong Kong company which is fronting the uses of Traditional Chinese Medicine (”TCM”) to treat not only ADHD and ASD but also Covid-19 which shook the world back in 2020.
Regencell is currently a listed Company in NASDAQ market in the US with its ticker $RGC.
At present, RGC has treatment formula has test treated 19 patients (suspected or confirmed COVID cases). 12 of 19 patients which were treated exhibited improvements in their recovery after an average treatment period of 5 days.
Mr Au, the company’s CEO and chairman has mentioned “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
Aside from the company’s positive progress in medical, the CEO (Mr Au) has shown his confidence in the progress of the company direction and not sold a single share since taking his company to Initial Public Offering (”IPO”) in Year 2020. Mr Au has pledged to not take salary and bonus (<1$) until the company reaches US$1 Billion market cap as his target.
Presently, the company’s business plan of expansion is to trade, manufacture, market and distribute the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]
Regencell is currently a listed Company in NASDAQ market in the US with its ticker $RGC.
At present, RGC has treatment formula has test treated 19 patients (suspected or confirmed COVID cases). 12 of 19 patients which were treated exhibited improvements in their recovery after an average treatment period of 5 days.
Mr Au, the company’s CEO and chairman has mentioned “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."
Aside from the company’s positive progress in medical, the CEO (Mr Au) has shown his confidence in the progress of the company direction and not sold a single share since taking his company to Initial Public Offering (”IPO”) in Year 2020. Mr Au has pledged to not take salary and bonus (<1$) until the company reaches US$1 Billion market cap as his target.
Presently, the company’s business plan of expansion is to trade, manufacture, market and distribute the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.
[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]
(0)
(0)